References
- CAR -T cells for cancer immunotherapy—the barriers ahead and the paths through. Int Rev Immunol. 2002;41(6):567–581. doi:10.1080/08830185.2022.2080820.
- Combinatorial approaches to effective therapy in GBM - Current status and what the future beholds. Int Rev Immunol. 2002;41(6):582–605. doi:10.1080/08830185.2022.2101647.
- Clinical utility of CART cells in brain tumors: Lessons learnt from the past, current evidence and the future stakes. Int Rev Immunol. 2002;41(6):606–624. doi:10.1080/08830185.2022.2125963.
- B7-H3-targeted CAR -T cell therapy for solid tumors. Int Rev Immunol. 2002;41(6):625–637. doi:10.1080/08830185.2022.2102619.
- Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. Int Rev Immunol. 2002;41(6):638–648. doi:10.1080/08830185.2022.2067154.